Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지

Efficacy and Safety of Cinacalcet for Secondary Hyperparathyroidism in Dialysis Patients and Drug Use Evaluation

투석환자의 이차성 부갑상선 기능 항진증 치료에서 cinacalcet의 유효성과 안전성 및 사용 적정성 평가

  • Seo, Hee Nam (Department of Pharmacy, Kangbuk Samsung Hospital)
  • Received : 2012.12.18
  • Accepted : 2013.05.22
  • Published : 2013.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Secondary hyperparathyroidism (SHPT) is common in patients with chronic kidney disease, affecting most of those who are receiving dialysis. Cinacalcet, a novel calcimimetic, targets the calcium-sensing receptor to lower PTH levels in dialysis patients. Objective: This study aimed to assess efficacy, safety and appropriateness of use of cinacalcet in dialysis patients. Method: This retrospective study was performed on total 24 cases with identified intact parathyroid hormone (iPTH), serum calcium and phosphorus levels before and 4 weeks after cinacalcet initiation at a teaching hospital from July 1st, 2011 to October 31st, 2012. Results: Cinacalcet decreased iPTH by 19% from baseline after 4weeks treatment and it was statistically significant (p<0.001). Cinacalcet also significantly decreased iPTH levels regardless of dialysis modality (hemodialysis group versus peritoneal dialysis group) and severity of SHPT (iPTH 300-800 pg/ml group versus iPTH >800 pg/ml group). Serum calcium, phosphorus and Ca x P levels were decreased without statistical significance. Gastrointestinal events, headache and hypocalcemia were the most common side effects. Monitoring for iPTH and serum calcium was not performed appropriately. 43.7% patients initiated cinacalcet therapy at serum calcium level< 9.0 mg/dl. Conclusion: In conclusion, cinacalcet lowers parathyroid hormone levels with no serious side effects. However, it is required to avoid cinacalcet treatment in patients with low serum calcium levels and monitor iPTH and serum calcium levels during cinacalcet administration.

Keywords

References

  1. Rodriguez M, Nemeth E, Martin D. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Renal Physiol 2005; 288: F253-64. https://doi.org/10.1152/ajpcell.00014.2004
  2. Salem MM. Hyperparathyroidism in the hemodialysis population: A survey of 612 patients. Am J Kidney Dis 1997; 29: 862-5. https://doi.org/10.1016/S0272-6386(97)90459-5
  3. Billa V, Zhong A, Bargman J, et al., High prevalence of hyperparathyroidism among peritoneal dialysis patients: A review of 176 patients. Perit Dial Int 2000; 20: 315-21.
  4. Pitts TO, Piraino BH, Mitro R, et al., Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab 1988; 67: 876-81. https://doi.org/10.1210/jcem-67-5-876
  5. St. John A, Thomas MB, Davies CP, et al., Determinants of intact parathyroid hormone and free 1,25-dihydroxyvitamin D levels in mild and moderate renal failure. Nephron 1992; 61: 422-7. https://doi.org/10.1159/000186960
  6. Naveh-Many T, Rahamimov R, Livni N, et al., Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphorus, and vitamin D. J Clin Invest 1995; 96(4): 1786-93. https://doi.org/10.1172/JCI118224
  7. Rickers H, Christiansen C, Christensen P, et al., Serum concentrations of vitamin D metabolites in different degrees of impaired renal function. Estimation of renal and extrarenal secretion rate of 24,25-dihydroxyvitamin D. Nephron 1985; 39(3): 267-71. https://doi.org/10.1159/000183383
  8. Coladonato JA, Ritz E. Secondary hyperparathyroidism and its therapy as a cardiovascular risk factor among endstage renal disease patients. Adv Ren Replace Ther 2002; 9: 193-99. https://doi.org/10.1053/jarr.2002.34842
  9. Joy MS, Karagiannis PC, Peyerl FW. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. J Manag Care Pharm 2007; 13: 397-411.
  10. Martin KJ, Gonzalez EA. Metabolic bone disease in chronic kidney disease. J Am Soc Nephrol 2007; 18: 875-85. https://doi.org/10.1681/ASN.2006070771
  11. Kalantar-Zadeh K, Kuwae N, Regidor DL, et al., Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-80. https://doi.org/10.1038/sj.ki.5001514
  12. Gutierrez OM, Mannstadt M, Isakova T, et al., Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-92. https://doi.org/10.1056/NEJMoa0706130
  13. Goodman WG, Ramirez JA, Belin TR, et al., Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 1994; 46(4): 1160-66. https://doi.org/10.1038/ki.1994.380
  14. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(suppl 3): S1- S201.
  15. Wetmore JB, Quarles LD. Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift. Nat Clin Pract Nephrol 2009; 5: 24.
  16. Brown AJ, Dusso A, Slatopolsky E. Vitamin D. Am J Physiol 1999; 277: F157-75.
  17. Slatopolsky E, Finch J, Brown A. New vitamin D analogs. Kidney Int 2003; 63(suppl 85): S83-7. https://doi.org/10.1046/j.1523-1755.63.s85.20.x
  18. Sprague SM, Llach F, Amdahl M, et al., Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003; 63(4): 1483-90. https://doi.org/10.1046/j.1523-1755.2003.00878.x
  19. Mittman N, Khana R, Rani S, et al., Comparison of paricalcitol and calcitriol therapy for the treatment of secondary hyperparathyroidism in patients on maintenance dialysis. In: American Society of Nephrology Renal Week conference, St. Louis, MO, October 27-November 1, 2004
  20. Joy MS, Kshirsagar AV, Franceschini N. Calcimimetics and the treatment of primary and secondary hyperparathyroidism. Ann Pharmacother 2004; 38: 1871-80. https://doi.org/10.1345/aph.1D108
  21. Amgen Inc. Sensipar(R) [package insert] Thousand Oaks, CA: Amgen Inc.; March 2004.
  22. Akiba T, Akizawa T, Tsukamoto Y, et al., Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism. Ther Apher Dial 2008; 12: 117-25. https://doi.org/10.1111/j.1744-9987.2008.00556.x
  23. Block GA, Martin KJ, De Francisco ALM, et al., Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. New Eng J Med 2004; 350: 1516-25 https://doi.org/10.1056/NEJMoa031633
  24. Raggi P, Chertow GM, Torres PU, et al., The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 2011; 26(4): 1327-39 https://doi.org/10.1093/ndt/gfq725
  25. Messa P, Castelnovo C, Scalamogna A. Calcimimetics in peritoneal dialysis patients. Contrib Nephrol 2012; 178: 143-9. https://doi.org/10.1159/000337834
  26. Lindberg JS, Culleton B, Wong G, et al., Cinacalcet HCl, an Oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A Randomized, Double-Blind, Multicenter Study. J Am Soc Nephrol 2005; 16: 800-7. https://doi.org/10.1681/ASN.2004060512
  27. Portoles J, Tato A, Lopez-Sanchez P, et al., Cinacalcet in patients on peritoneal dialysis with moderate to severe hyperparathyroidism resistant to conventional treatment, a one-year, prospective study. Nefrologia 2008; 28(4): 419-24.
  28. Ministry of food and drug safety/ezdrug (http://ezdrug.mfds. go.kr/)
  29. Heo JH, Kim SJ, Kim JH, et al., Effect of patient's satisfaction with pharmacist's medication counseling on medication compliance among outpatients. Korean J Clin Pharm 2009; 19(2): 110-9.
  30. Kim HJ, Kang JS, Park JY, et al., Survey on the satisfaction of the medication counseling for outpatient prescription. Korean J Clin Pharm 2006; 16(2): 90-95.
  31. Lee JE, Cho YJ, Han HJ, et al., Ca and P Levels in ESRD patients and the evaluation of a patient education. J Kor Soc Health-Syst Pharm 1999; 16(4): 489-94.